398 related articles for article (PubMed ID: 31942831)
21. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.
Choi W; Czerniak B; Ochoa A; Su X; Siefker-Radtke A; Dinney C; McConkey DJ
Nat Rev Urol; 2014 Jul; 11(7):400-10. PubMed ID: 24960601
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer.
McConkey DJ; Choi W; Ochoa A; Siefker-Radtke A; Czerniak B; Dinney CP
Hematol Oncol Clin North Am; 2015 Apr; 29(2):377-94, x-xi. PubMed ID: 25836941
[TBL] [Abstract][Full Text] [Related]
23. The Cancer Genome Atlas Project in Bladder Cancer.
Rodriguez-Vida A; Lerner SP; Bellmunt J
Cancer Treat Res; 2018; 175():259-271. PubMed ID: 30168126
[TBL] [Abstract][Full Text] [Related]
24. Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C
Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
[TBL] [Abstract][Full Text] [Related]
25. A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Up Staging.
de Jong JJ; Liu Y; Boorjian SA; Bivalacqua TJ; Porten SP; Wheeler T; Davicioni E; Svatek RS; Boormans JL; Black PC; Lotan Y; Gibb EA
J Urol; 2020 Aug; 204(2):239-246. PubMed ID: 32074006
[TBL] [Abstract][Full Text] [Related]
26. Biological molecular layer classification of muscle-invasive bladder cancer opens new treatment opportunities.
Trilla-Fuertes L; Gámez-Pozo A; Prado-Vázquez G; Zapater-Moros A; Díaz-Almirón M; Arevalillo JM; Ferrer-Gómez M; Navarro H; Maín P; Espinosa E; Pinto Á; Vara JÁF
BMC Cancer; 2019 Jun; 19(1):636. PubMed ID: 31253132
[TBL] [Abstract][Full Text] [Related]
27. [Molecular subtype classification of urothelial bladder cancer and its clinical relevance].
Szarvas T; Oláh C; Riesz P; Géczi L; Nyirády P
Orv Hetil; 2019 Oct; 160(42):1647-1654. PubMed ID: 31608691
[TBL] [Abstract][Full Text] [Related]
28. [Update on molecular classifications and new histological classification of bladder cancer].
Varinot J; Furudoï A; Roupret M; Compérat E
Prog Urol; 2016; 26(11-12):600-607. PubMed ID: 27663304
[TBL] [Abstract][Full Text] [Related]
29. FOXA1, GATA3 and PPARɣ Cooperate to Drive Luminal Subtype in Bladder Cancer: A Molecular Analysis of Established Human Cell Lines.
Warrick JI; Walter V; Yamashita H; Chung E; Shuman L; Amponsa VO; Zheng Z; Chan W; Whitcomb TL; Yue F; Iyyanki T; Kawasawa YI; Kaag M; Guo W; Raman JD; Park JS; DeGraff DJ
Sci Rep; 2016 Dec; 6():38531. PubMed ID: 27924948
[TBL] [Abstract][Full Text] [Related]
30. [Point somatic mutations in bladder cancer: key carcinogenesis events, diagnostic markers and therapeutic targets].
Mikhailenko DS; Nemtsova MV
Urologiia; 2016 Feb; (1):100-105. PubMed ID: 28247712
[TBL] [Abstract][Full Text] [Related]
31. Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development.
Zieger K; Marcussen N; Borre M; Ørntoft TF; Dyrskjøt L
Int J Cancer; 2009 Nov; 125(9):2095-103. PubMed ID: 19637316
[TBL] [Abstract][Full Text] [Related]
32. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
López-Knowles E; Hernández S; Malats N; Kogevinas M; Lloreta J; Carrato A; Tardón A; Serra C; Real FX
Cancer Res; 2006 Aug; 66(15):7401-4. PubMed ID: 16885334
[TBL] [Abstract][Full Text] [Related]
33. [Personalised medicine in urothelial bladder cancer].
Grunewald CM; Niegisch G
Aktuelle Urol; 2019 Sep; 50(5):502-508. PubMed ID: 31195416
[TBL] [Abstract][Full Text] [Related]
34. Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomies.
Han L; Gallan AJ; Steinberg GD; Sweis RF; Paner GP
Hum Pathol; 2020 Dec; 106():54-61. PubMed ID: 32987034
[TBL] [Abstract][Full Text] [Related]
35. Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.
Genitsch V; Kollár A; Vandekerkhove G; Blarer J; Furrer M; Annala M; Herberts C; Pycha A; de Jong JJ; Liu Y; Krentel F; Davicioni E; Gibb EA; Kruithof-de Julio M; Wyatt AW; Seiler R
Urol Oncol; 2019 Sep; 37(9):573.e19-573.e29. PubMed ID: 31358384
[TBL] [Abstract][Full Text] [Related]
36. H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases.
Castillo-Martin M; Collazo Lorduy A; Gladoun N; Hyun G; Cordon-Cardo C
J Pediatr Urol; 2016 Apr; 12(2):91.e1-7. PubMed ID: 26522772
[TBL] [Abstract][Full Text] [Related]
37. Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise.
Kim J; Akbani R; Creighton CJ; Lerner SP; Weinstein JN; Getz G; Kwiatkowski DJ
Clin Cancer Res; 2015 Oct; 21(20):4514-24. PubMed ID: 26473186
[TBL] [Abstract][Full Text] [Related]
38. [Molecular genetics of urinary bladder cancer progression].
Sauter G; Simon R; Bubendorf L; Mihatsch M
Verh Dtsch Ges Pathol; 2002; 86():49-56. PubMed ID: 12647351
[TBL] [Abstract][Full Text] [Related]
39. Papillary and muscle invasive bladder tumors with distinct genomic stability profiles have different DNA repair fidelity and KU DNA-binding activities.
Bentley J; L'Hôte C; Platt F; Hurst CD; Lowery J; Taylor C; Sak SC; Harnden P; Knowles MA; Kiltie AE
Genes Chromosomes Cancer; 2009 Apr; 48(4):310-21. PubMed ID: 19105236
[TBL] [Abstract][Full Text] [Related]
40. FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients.
Smal MP; Rolevich AI; Polyakov SL; Krasny SA; Goncharova RI
Exp Oncol; 2014 Dec; 36(4):246-51. PubMed ID: 25537218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
